Centocor Inc. said Friday that its Myoscint cardiac imagingagent will be reviewed on Nov. 26 by the Food and DrugAdministration's biological response modifiers advisorycommittee. The committee will discuss the use of Myoscint asan adjunct to the diagnosis of myocardial infarct.
Myoscint, which is sold in eight European countries, is aradiolabeled imaging agent that uses a fragment of amonoclonal antibody to seek out and bind to dead heart tissue.
Malvern, Pa.-based Centocor expects to file a product licenseapplication on its Fibriscint imaging agent later this year. Thecompany has completed clinical trials of Fibriscint to diagnosedeep venous thrombosis.
The company's shares (NASDAQ:CNTO) closed up 50 cents at$53.50 on Friday.
(c) 1997 American Health Consultants. All rights reserved.